Dysfunction

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Monday, October 23, 2023

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia via once-daily, oral administration. Initial data from the single- and multiple-ascending dose evaluations in healthy volunteers and the first cohort of four patients with narcolepsy type 1 (NT1) will be presented today at the 2023 World Sleep Congress in Rio de Janeiro.

Key Points: 
  • In the four patients with NT1, treatment with ALKS 2680 demonstrated improved sleep latency compared to placebo at all doses tested, with a clear dose response.
  • The differences between ALKS 2680 and placebo were statistically significant for all doses: 1 mg (p
  • Treatment with ALKS 2680 resulted in clinically meaningful improvements in MWT from baseline at all doses tested.
  • "These initial data support our design rationale for ALKS 2680 as a highly potent, orally bioavailable, selective orexin 2 receptor agonist designed to address the underlying pathology of narcolepsy.

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Monday, October 23, 2023

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia via once-daily, oral administration. Initial data from the single- and multiple-ascending dose evaluations in healthy volunteers and the first cohort of four patients with narcolepsy type 1 (NT1) will be presented today at the 2023 World Sleep Congress in Rio de Janeiro.

Key Points: 
  • In the four patients with NT1, treatment with ALKS 2680 demonstrated improved sleep latency compared to placebo at all doses tested, with a clear dose response.
  • The differences between ALKS 2680 and placebo were statistically significant for all doses: 1 mg (p
  • Treatment with ALKS 2680 resulted in clinically meaningful improvements in MWT from baseline at all doses tested.
  • "These initial data support our design rationale for ALKS 2680 as a highly potent, orally bioavailable, selective orexin 2 receptor agonist designed to address the underlying pathology of narcolepsy.

Health research must be ethical – we can do more to make sure that's the case for young trans people and their families

Retrieved on: 
Wednesday, July 12, 2023

Since the Four Corners episode, the New South Wales health minister has announced a review of the scientific evidence related to health care for young trans people.

Key Points: 
  • Since the Four Corners episode, the New South Wales health minister has announced a review of the scientific evidence related to health care for young trans people.
  • How can we ensure ethical principles for young trans people and their families are met – especially when they might see research as one of few avenues for accessing care?
  • How do young trans people and their families know when they should or shouldn’t sign up?

Obligations and oversight

    • They include a chairperson, members of the public and people with expert knowledge and current experience in research.
    • These say research should be respectful, culturally safe and undertaken in the best interest of the individuals and communities.
    • This includes trans young people, many of whom experience anxiety and depression as a result of stigma and discrimination.

What about young trans people and their families?

    • Accordingly, it is expected research with young trans people and their families is undertaken ethically, responsibly and with integrity.
    • Young trans people and their families need to be involved throughout the research process.
    • When young trans people and their families are not meaningfully included as research partners, research findings can be misinterpreted.

How can young trans people and their families assess research ethics?


    Participants should be presented with clear information about what the study will involve and the implications of participation. Before deciding on whether to participate in research, young trans people and their families should know their rights in research settings including the right to complain and what happens to their personal data if they withdraw. Helpful questions to ask before consenting to participate in research include:
    Participation in research should be a choice. It should not involve any kind of coercion, such as feeling that not participating in the research would mean a person would not get the same access to gender-affirming health care.

Robust research is needed

    • Robust research is vital to reducing this health inequity and improving the health and wellbeing of young trans people.
    • To ensure this research is of the highest standard, ethics committees must have the expertise to uphold ethical principles in research involving trans children and adolescents.
    • As the Four Corners program shows, high-quality guidelines specifically for research with trans people, including children and adolescents, are urgently needed.

Boulder Crest Foundation Declares June 13 National Posttraumatic Growth Day

Retrieved on: 
Tuesday, June 13, 2023

BLUEMONT, Va., June 13, 2023 /PRNewswire-PRWeb/ -- More than 20 percent of Americans struggle with their mental health, and far too many of them feel as though they are destined to live diminished lives. It's time to change the conversation, and move beyond labels and diagnoses like PTSD, Depression, and Anxiety, so we can enable people to turn their struggle into strength and Posttraumatic Growth (PTG). To make that possible, Boulder Crest Foundation, the "home of Posttraumatic Growth," is pleased to announce that as of 2023, June 13 will annually mark National Posttraumatic Growth Day.

Key Points: 
  • To make that possible, Boulder Crest Foundation , the "home of Posttraumatic Growth," is pleased to announce that as of 2023, June 13 will annually mark National Posttraumatic Growth Day.
  • We can and must do better to spread the word about Posttraumatic Growth, and the establishment of National Posttraumatic Growth Day is a great start."
  • National Posttraumatic Growth Day acknowledges that what doesn't kill us, makes us stronger and wiser.
  • "The establishment of National Posttraumatic Growth Day is an important part of starting to change the conversation around trauma," said Dr. Richard Tedeschi, Executive Director, Boulder Crest Institute, and co-founder of the science of PTG.

'He is always there to listen': friendships between young men are more than just beers and banter

Retrieved on: 
Tuesday, May 9, 2023

With this in mind, it’s not entirely surprising that some people seem to think men have a problem with friendships.

Key Points: 
  • With this in mind, it’s not entirely surprising that some people seem to think men have a problem with friendships.
  • While women may be especially quick to draw this conclusion, the idea exists in society as a whole.
  • Men, we are led to believe, either have low quality friendships, or not enough of them.
  • We then do not see how men demonstrate closeness less obviously, in coded ways, or even silently.

Humour is one example

    • Contrary to the notion that it’s used to “put up walls”, humour, such as the use of provocative nicknames, can promote a sense of closeness.
    • Humour in the military, for instance, is used to express the hardships of the work and channel aggression, all the while creating a sense of togetherness.

Resisting masculinity

    • But readings of male friendships as shallow assume that men are unable to negotiate the rules of masculinity.
    • The truth is that regimes of masculinity are largely imposed on men, and they do their best to play the game, or subvert masculinity if they can.
    • Many men resist competitive masculinity enough to express vulnerabilities and create deep connections.

The rise of the bromance

    • No phenomenon illustrates this better than the rise of the “bromance”.
    • The term may have emerged from skateboarding in the 1990s, when heterosexual men commonly shared hotel rooms while on tour.
    • Young men talk about how their bromances are on another level to friendships in terms of trust, expression of vulnerability and physical affection.

‘Levelling up’ male friendships

    • Research shows younger men are engaging in close male friendships and expressing their feelings like never before.
    • They will open up to others in safe contexts – although not all men have these safe spaces.
    • For example, it seems that by encouraging men to do activities side by side, or that have a “purpose” (such as volunteering or attending men’s sheds to create things), male bonding and important conversations naturally emerge.

ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease

Retrieved on: 
Thursday, April 13, 2023

In the paper titled, “Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer’s disease,” the authors reviewed data associated with microglial pathways that have potential as drug targets for treatment of MCI and AD.

Key Points: 
  • In the paper titled, “Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer’s disease,” the authors reviewed data associated with microglial pathways that have potential as drug targets for treatment of MCI and AD.
  • “It is encouraging to see the extensive research underway to identify potential drug targets.
  • We are proud of the original scientific contributions in this area by the inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100, Drs.
  • Robert W. Keane and Juan Pablo de Rivero Vaccari at the University of Miami Miller School of Medicine.” To review their latest publication on Alzheimer’s disease, Click Here .

Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences

Retrieved on: 
Tuesday, October 11, 2022

Apollo Health Ventures and the Paul Scherrer Institute (PSI) launched Focal Biosciences.

Key Points: 
  • Apollo Health Ventures and the Paul Scherrer Institute (PSI) launched Focal Biosciences.
  • Apollo Health Ventures and the Paul Scherrer Institute will join their resources together with scientific founder Prof. G.V.
  • Shivashankar, Scientific Founder of Focal Biosciences, Head of the Laboratory of Nanoscale Biology, Paul Scherrer Institute and Professor of Mechano-Genomics, ETH Zurich.
  • Apollo Health Ventures is a transatlantic venture capital firm specialized in developing and investing in data-driven biotechnology and health tech ventures.

Worldwide Hereditary Angioedema Industry to 2030 - Players Include CSL Behring, Takeda Pharmaceutical, Pharming and Ionis Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 31, 2022

Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes.

Key Points: 
  • Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes.
  • The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally.
  • The World Allergy Organization (WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein inhibitors and other drugs approved to treat hereditary angioedema.
  • Key players are adopting strategic collaborations and acquisitions for development and expansion of the hereditary angioedema (HAE) portfolio and to accelerate respective pipelines for faster delivery of products.

IDACORP, Inc. Announces Second Quarter 2022 Results, Increases Bottom-End of 2022 Earnings Guidance

Retrieved on: 
Thursday, August 4, 2022

As of May 5, 2022, the date of filing IDACORP's and Idaho Power's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022.

Key Points: 
  • As of May 5, 2022, the date of filing IDACORP's and Idaho Power's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022.
  • IDACORP will hold an analyst conference call today at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time).
  • All parties interested in listening may do so through a live webcast on IDACORP's website ( www.idacorpinc.com ), or by calling (855) 761-5600 for listen-only mode.
  • The conference call logistics are also posted on IDACORP's website and will be included in IDACORP's earnings news release.

Paradigm Partners with NFL Alumni Health on Osteoarthritis Program

Retrieved on: 
Thursday, July 14, 2022

NEW YORK, July 14, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company) a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, is pleased to announce it has entered into a corporate partnership with NFL Alumni Health (NFLAH). This partnership will inform NFL Alumni Association (NFLAA) members about osteoarthritis disease onset and progression, current treatment options, and provide information about actively enrolling clinical trials throughout the U.S.

Key Points: 
  • Paradigm as an NFL Alumni Health corporate member has entered into a research partnership to inform NFL Alumni members about osteoarthritis (OA) and potential clinical trial participation.
  • NFL Alumni Health is a wholly owned subsidiary of NFL Alumni offering informational resources, programs, services, and other benefits to both NFL Alumni members (former NFL players, coaches, executives, spouses, cheerleaders, and associate members) and the general public.
  • Paradigm was introduced to NFL Alumni Health by expanded access program (EAP) participants, who have become strong advocates of Zilosul for knee osteoarthritis (KOA) treatment based on their positive experiences.
  • NFL Alumni Health oversee the vetting process to ensure they bring credible and meaningful health sector-related partnerships to their membership.